地拉罗司对铁质积聚能有多大的疗效？

(Enreg) is an oral iron chelator. Its primary use is to reduce chronic iron overload in patients receiving chronic transfusions for beta thalassemia and other chronic anemias. It is the first oral drug approved for this purpose in the United States. According to the FDA report, patients taking deferasirox oral suspension tablets experienced renal failure and cytopenias. Today we will take a closer look at how effective deferasirox can be on iron accumulation?

According to the International Working Group's 2006 criteria, 51 patients (28%) had improved hemograms, of which only 7 patients received growth factors or MDS. During the 3-year study, 138 (79.8%) patients discontinued treatment, 43 (24.8%) of whom discontinued treatment due to adverse events or disease progression, and 23 (13.2%) due to abnormal laboratory test values. The most common drug-related adverse events were gastrointestinal disturbances and increased serum creatinine. Twenty-eight patients died, but none were related to deferasirox treatment.

The results of this trial show that deferasirox (Enrige) can reduce serum ferritin and LPI in transfusion-dependent MDS patients, and some patients' hemogram and liver function can be improved to a certain extent.

A multicenter, prospective clinical trial was conducted to evaluate the safety and efficacy of deferasirox (Enreg) in patients with low- or intermediate-risk-1 myelodysplastic syndrome (MDS). The study selected patients with serum ferritin ≥1000 μg/L, transfusion dependence and red blood cell transfusions ≥20U to be included. The starting dose of deferasirox is 20 mg/kg/d, which can be adjusted up to 40 mg/kg/d. A total of 176 patients were enrolled in the study, of whom 173 received treatment. 53% of patients completed 12 months of treatment (n = 91) with a 23% decrease in mean serum ferritin, 36.7% completed 2 years of treatment (N = 49), and 36.5% completed 3 years of treatment (N = 33).

The study found that the reduction of serum ferritin was significantly positively correlated with the improvement of ALT (P <0.001). Baseline labile plasma iron (LPI) was elevated in 68 patients (39.3%). After 13 weeks, all patients with abnormal baseline LPI levels returned to normal.

Deferasirox (Enreg), a new oral formulation from Exjade, is the first directly swallowable once-daily oral iron chelator. Exjade is a dispersible tablet that must be mixed with liquid and taken on an empty stomach at least 30 minutes before meals. Deferasirox can be swallowed directly with or without a light meal, greatly simplifying the treatment and management of chronic iron overload (CIO).

The above is the content of (Enrig) effect, I hope it can help you!

Recommended related hot articles: /newsDetail/80680.html